secwatch.observer — SEC 8-K summary
======================================

Issuer:     Processa Pharmaceuticals, Inc. (PCSA)
CIK:        0001533743
Form:       8-K
Filed at:   2024-07-17T23:59:59+00:00
Accession:  0001493152-24-028093
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Processa appoints Russell Skibsted as CFO; James Stanker retires
----------------------------------------------------------------

- Russell Skibsted appointed CFO effective July 16, 2024; succeeds James Stanker who retired.
- Skibsted brings 30 years of pharma finance experience; most recently CFO of Alimera Sciences.
- Annual base salary $400,000; eligible for 35% target bonus and 28,000 RSUs upon goal achievement.
- Stanker remains part-time employee during transition period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533743/000149315224028093/0001493152-24-028093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533743/000149315224028093/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-028093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer